Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14915983 | 0.92 | ALDH1A1 (0.35) | TP53LMNAALDH1A1GAAMAPT | |
| SCHEMBL359944 | 0.81 | KMT2A (0.35) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL360883 | 0.80 | ALDH1A1 (0.36) | TP53LMNAALDH1A1GAAMAPT | |
| SCHEMBL359609 | 0.80 | — | — | |
| SCHEMBL360687 | 0.79 | KMT2A (0.32) | ALDH1A1 | |
| SCHEMBL360112 | 0.77 | ALDH1A1 (0.32) | LMNAALDH1A1GAAMAPTTHRB | |
| SCHEMBL359796 | 0.77 | LMNA (0.34) | TP53LMNASORT1ALDH1A1GAA | |
| SCHEMBL15957863 | 0.69 | SMN1; SMN2 (0.41) | ALDH1A1GAAMAPTTHRBSMN1; SMN2 | |
| SCHEMBL10080300 | 0.68 | KMT2A (0.33) | ALDH1A1 | |
| SCHEMBL10079890 | 0.67 | NPC1 (0.34) | LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
| US-10723703-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-10183913-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-22 | — | — | US | disclosed |
| US-10087146-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180273489-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2018-09-27 | — | — | US | disclosed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2594559-B1 | PYRAZOLE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20140315971-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2014-10-23 | — | — | US | disclosed |
| US-8809383-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008528-A1 | PYRAZOLE COMPOUND | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315971-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-10183913-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-20170217902-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-10723703-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-20180273489-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-20190084938-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-10087146-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | TP53 4790/4885LMNA 4613/4885SORT1 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.